Marc Voigt, CEO and Deanne Miller, COO will be attending and hosting meetings at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 at the Westin St. Francis in San Francisco, CA. 

Marc Voigt, CEO of Immutep will participate in the event virtually and will deliver a corporate presentation.

Speaking time of Marc Voigt: 11:20 AM ET on Wednesday, 7 Deccember 2022

For questions, please email DBroderick@LJFevents.com

Link to the webcast

Immutep Annual General Meeting 2022 will be taking place at Offices of Piper Alderman, Governor Macquarie Tower, 1 Farrer Place, Sydney, NSW on Wednesday, 23 November 2022, 11.00 am (AEDT)

Notice of Meeting

Marc Voigt, CEO of Immutep will participate in the upcoming in-person conference

Speaking time of Marc Voigt: 1:30pm - 2.00pm (UTC) on Thursday, 17 November 2022

A replay of the webcast is available here

For questions, please email londonhealthcareconf@jefferies.com 

Marc Voigt, CEO and Deanne Miller, COO of Immutep will participate in the upcoming conference to present a corporate overview

Link to Webcast

Link to Presentation

Marc Voigt, CEO and Deanne Miller, COO will participate in the in-person conference 

Immutep will participate in the 2nd Non-Small Cell Lung Cancer Drug Development Summit

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC

Speaking time of Frederic Triebel: 12.00 EST, Thursday 22nd September 2022

Click here for the Presentation

Click here for the Event Guide

Marc Voigt, CEO and Deanne Miller, COO of Immutep will participate in the virtual Investor' Forum

Marc Voigt, CEO of Immutep will participate in the conference virtually and Deanne Miller, COO will participate in person.

Speaking time of Marc Voigt: 15:50 pm – 16:20 pm AEST on Tuesday, 6 September 2022

Immutep will attend to the 2022 World Conference on Lung Cancer.

Marc Voigt, CEO of Immutep will participate in the upcoming in-person conference and will be available for one to one investor meetings in New York City on June 8-10, 2022.

Speaking time of Marc Voigt: 8:30 AM ET on 10 June, 2022

For questions, please email healthcareconference@jefferies.com

A live webcast and replay of the presentation will be made available at https://wsw.com/webcast/jeff240/immp/1851075 and on the Company’s website following the event.

Venue: McCormick Place, Chicago, IL, USA

Immutep will participate in this year`s event.

Immutep will attend to the ESMO Breast Cancer Congress 2022.

The conference will be a virtual format and involve an informal panel discussion followed by Q&A from the audience.

To join the live event, please contact your Goldman Sach’s representative.

Speaking time of Marc Voigt/ CEO: 3:45pm AEST on 29th April

Marc Voigt, CEO of Immutep will participate in the upcoming digital event.

Immutep is presenting new data at the European Lung Cancer Congress 2022.

The Abstract is available here

CEO Marc Voigt will participate in a fireside chat plus corporate presentation.
Fireside chat time & date: 11:00 am Eastern Daylight Time (EDT) on Monday 28 March 2022.

Marc Voigt, CEO of Immutep will participate in the upcoming digital event.

9:10 am – 9:40 am Eastern Standard Time (EST) on Tuesday 8 March 2022
Webcast: A live webcast of this event, as well as an archived recording, will be available at https://wsw.com/webcast/cowen108/immp/2022543

Management will also be available for 1-on-1 meetings with institutional investors. Investors interested in scheduling a meeting should contact their Cowen representative.

Marc Voigt, CEO of Immutep will participate in the upcoming digital event and will deliver opening remarks.

Speaking time of Marc Voigt: 9.00  EST/6.00 PST, Wednesday,  26th January 2021

Frederic Triebel, Frédéric Triebel, CSO & CMO of Immutep will deliver a keynote.

Speaking time of Frederic Triebel: 12.00 EST/9.00 PST, Wednesday,  26th January 2021

Immutep will participate in the BIO One-on-One Partnering at J.P. Morgan Healthcare Conference.

Immutep will participate in the virtual Corporate Access Event.

Asia’s Thought-Leadership Platform on Health Innovation and Investment

Deanne Miller, COO and Marc Voigt, CEO of Immutep will attend to the digital event.

Immutep will present this AIPAC data in global webcast for investors, details are as follows:

Date & Time:  17 November 2021, at 8.00 am Australian Eastern Daylight Time (AEDT) (Tuesday, November 16, 2021

4:00 PM EST)

Click here for Webcast slides

A replay of the webcast is available here.

Marc Voigt, CEO of Immutep will attend to the digital event.

The conference will be a virtual format and involve an informal discussion with Goldman Sachs host (Chris Cooper, Healthcare Analyst Global Investment Research), and Q&A with investors.

To join the live event, please contact your Goldman Sach’s representative.

Speaking time of Marc Voigt/ CEO: 4pm AEST on 7th October

Immutep will participate in the virtual event format.

Click here for the presentation 

Immutep will participate in the virtual ESMO 2021 congress.

Click here for the "INSIGHT - Stratum D" poster which will be presented at the ESMO 2021

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.

Date : Tuesday, September 14^th

Click here for the presentation 

Click here for the EGM - Notice of Meeting 2021 Update 

Click here for the EGM - Notice of Meeting 2021

Immutep will participate in the new virtual event format.

Immutep will participate in this year`s virtual ASCO 2021 Annual Meeting.

Click here for the "TACTI-002_HNSCC" poster which will be presented at the virtual event - ASCO 2021

Click here for the "TACTI-002_NSCLC" poster which will be presented at the virtual event - ASCO 2021

Click here for the "Insight" poster which will be presented at the virtual event - ASCO 2020

Immutep will participate in this year`s virtual event format.

Immutep will participate in the virtual event format.

Marc Voigt, CEO of Immutep has been invited to present at the  Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC

Fireside Chat at day 3,  19th | 9:30 AM - 10:00 AM EST

Click here for the Agenda of day 3 - March 19th

Immutep will participate in the virtual IO 360° conference.

Immutep will participate in the virtual 10th Annual Lifesci Partners Corporate Access Event

Webcast Details

Immutep will present this AIPAC data in a global webcast for investors, details are as follows:

Date & Time: Friday, 11 December 2020, at 8.30 am Australian Eastern Daylight Time (AEDT) (Thursday, December 10^th, at 4:30 p.m. U.S. ET)

Register: http://public.viavid.com/index.php?id=142664

Click here for AIPAC Global Webcast Slides

Immutep will participate in this year`s virtual SABCS 2020 symposium.

Click here for the poster "Primary efficacy results from AIPAC" which will be presented at the SABCS Symposium 2020

Immutep will participate in the virtual SITC 2020 conference.

Click here for the "TACTI-002" poster which was presented at the SITC 2020.

Immutep will participate in the new virtual event format and will present:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): results of a phase II study in NSCLC and HNSC

Click here for the video presentation held by Frederic Triebel (CSO & CMO)

Delivered Digitally - European Standard Time

Immutep will participate in the virtual Bio-Europe 2020 conference.

Immutep will participate in the virtual ESMO 2020 conference.

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.

Presentation Time (EDT): 15^th September, 9:30 to 9:50 AM

Click here for the video presentation held by Marc Voigt (CEO)

Venue: Taipei Nangang Exhibition Center, Hall 2, 4F, Taipei City 11568, Taiwan

Immutep will participate in the new virtual event format.

Immutep will participate in the new virtual event format and will present:

“Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab”

&

"Open label, phase I study evaluating feasibility and safety of subcutaneous IMP 321
(a soluble LAG 3 protein, eftilagimod alpha) combined with avelumab in advanced stage
solid tumor entities results from stratum D of the INSIGHT platform trial"

Click here for the "TACTI-002" poster which will be presented at the virtual event - ASCO 2020

Click here for the "Insight" poster which will be presented at the virtual event - ASCO 2020

Immutep will participate in the virtual IOIF conference.

Venue: Hub27 Berlin, Messedamm 22, 14055, Berlin, Germany

Venue: San Diego Convention Center, San Diego, California, USA

Immutep will present this AIPAC data in a global webcast, details are as follows:

Date & Time: Thursday, March 26^th, 8am Australian Eastern Daylight Time / Wednesday, March 25^th, 5pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: http://public.viavid.com/index.php?id=138665

Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.

A replay of the webcast will also be available at www.immutep.com from the day after the event.

Click here for AIPAC Global Webcast Slides

The Company will present the interim TACTI-002 data and provide a further update on its clinical programs in a global webcast. The details for the webcast are as follows:

Date & Time: Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time / Tuesday, February 25, 2020, 4:00 pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link:
https://fnn.webex.com/fnn/onstage/g.php?MTID=e11208a0ff7fcccaca4d5e4b8a14e988f

Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.

A replay of the webcast will also be available at www.immutep.com from the day after the event.

Venue: City Cube Berlin, Messedamm 26, 14055 Berlin, Germany

Venue: Westin St. Francis Hotel | San Francisco, California, USA

Venue:  Henry B. Gonzalez Convention Center, 900 E Market St, San Antonio, Texas, USA

Click here to view the poster which will be presented at SABCS.

Venue: CCH - Congress Center Hamburg, Am Dammtor / Marseiller Str., 20355 Hamburg, Germany

https://www.das-neue-cch.de

The company will have presentations at the conference and representatives will be attending.

Venue: Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA

https://www.nationalharbor.com/gaylord-national/

Click here for the "TACTI-002" poster which will be presented at the SITC 2019

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.  

Venue: Melbourne Convention & Exhibition Centre, Melbourne VIC 3006, Australia

https://www.ausbiotechinvestment.com.au/event-details 

Day 1 – Tuesday, 15th October/ 2.50 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology

Click here for full agenda

Venue: Basel Congress Centre, Basel, Switzerland

Representatives of the company will be attending the conference.

Venue:

www.firabarcelona.com

Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat, Spain

Click here for the "TACTI-002" poster which will be presented at the ASCO 2019

Click here for the "Insight Trial" poster which will be presented at the ASCO 2019

Venue: McCormick Place, Chicago, IL, USA

Conference Day 2: Friday 17th May 2019/ 11.25.a.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials

Click here for the Presentation at World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

Venue: Business Design Centre, London, UK

Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.

Venue: The New York Academy of Sciences, New York, New York, USA

Venue: BBC (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany

Venue: San Diego Convention Center, San Diego, California, USA

Day 2 – Tuesday 5th March/ 3.00 p.m.  

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

click here for presentation

Venue:  Grand Hyatt, San Diego, USA

Venue:    San Francisco, California, USA

conference day 1/ 02.00 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab

Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Macquarie Office -  Sydney, Australia

click here for agenda

The company will have presentations at the conference and representatives will be attending.

Venue:    Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA

Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:

"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."

Venue: Manchester Central Convention Complex, Manchester, United Kingdom

Representatives of the company will be attending the conference.

Venue:   Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day. 

Venue:  Millenium Broadway Hotel & Conference Center, NY, USA

Press release: click here

Download "Newsmaker Immutep Corporate Presentation"

Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018

 - the largest networking event for life sciences and healthcare industries in the German capital region -

Venue:    Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”

Frédéric Triebel speaks on the subject:
“LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?”

Venue:  McCormick Place, Chicago, IL, USA

Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9^th

Venue:  Essex House, New York, NY, USA